Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001350516
Ethics application status
Approved
Date submitted
7/10/2024
Date registered
8/11/2024
Date last updated
11/11/2026
Date data sharing statement initially provided
8/11/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
First in Human Study with the EnCompass-S Clamp in patients undergoing Atrial Fibrillation ablation during a simultaneous cardiac surgical procedure.
Query!
Scientific title
First in Human Study to evaluate the performance of Encompass-S Clamp in patients undergoing AF ablation during a concomitant cardiac surgical procedure.
Query!
Additional trial identifiers [1]
312976
0
CP-2024-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Atrial Fibrillation
335157
0
Query!
Condition category
Condition code
Cardiovascular
331650
331650
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Ablation of atrial fibriliation in patients undergoing the procedure as an concommittant cardiac surgical procedure using the AtriCure Isolator Synergy EnCompass-S Ablation System inclusive of generators, clamp and assessories as below:
AtriCure Isolator Synergy EnCompass-S Ablation System:
• Generators:
AtriCure RF generator (ASU3)
AtriCure RF generator (ASB3)
• Clamp:
Isolator Synergy EnCompass-S Clamp (OLH-S)
• Accessories:
Clamp Guide (GPM100)
Handpiece Adapter
Footswitch Adapter
Footswitch
Generators are capital equipment and will be used in all procedures. Clamp and accessories are disposable and will be discarded after each case.
The AF ablation procedure using the AtriCure Isolator Synergy EnCompass-S Ablation System will be perfomed by qualified Cardithoracic Surgeons who frequently complete these procedures as a clinical standard of care.
The AtriCure Isolator Synergy EnCompass-S Ablation System will be used in one planned surgical procedure per patient, the number intra-procedural of energy delivery occurances will vary dependent on the number of lesions required to clinically treat the patient.
The planned cardiac surgical procedures using the AtriCure Isolator Synergy EnCompass-S Ablation System will be completed in tertiary public cardiac hospital. Investigational part of the procedure is approximately 20 minutes. Total procedure time is approximately 3-4 hours (concomitant + surgical ablation)
Query!
Intervention code [1]
329514
0
Treatment: Devices
Query!
Description of the comparator or control
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
339576
0
Safety
Query!
Assessment method [1]
339576
0
Physician assessment and monitoring of safety events related to the AtriCure Isolator Synergy EnCompass-S Ablation Syste including death, myocardial infarction, stroke, cardiac perforation requiring transfusion, and cardiac tamponade.
Query!
Timepoint [1]
339576
0
Through to 30 days post procedure at the following timepoints, procedure day, pre-discharge (discharge day or at 7 days post procedure, whichever is sooner), 30 days post procedure +- 7 days, unscheduled assessments as required by the Principal Investigator,
Query!
Secondary outcome [1]
440486
0
Procedural times
Query!
Assessment method [1]
440486
0
Recording of intraoperative times including cardiopulmonary bypass time as documented in standard of care procedure notes from medical, perfusionist and nursing staff.
Query!
Timepoint [1]
440486
0
During the surgical procedure using the AtriCure Isolator Synergy EnCompass-S Ablation System.
Query!
Secondary outcome [2]
441174
0
Recording of intraoperative times including cross clamp time
Query!
Assessment method [2]
441174
0
Time recorded during the surgical procedure as documented in standard of care procedure notes from medical, perfusionist and nursing staff.
Query!
Timepoint [2]
441174
0
During the surgical procedure using the AtriCure Isolator Synergy EnCompass-S Ablation System.
Query!
Secondary outcome [3]
441175
0
Recording of intraoperative times including ablation procedure time
Query!
Assessment method [3]
441175
0
Time recorded during the surgical procedure as documented in standard of care procedure notes from medical, perfusionist and nursing staff.
Query!
Timepoint [3]
441175
0
During the surgical procedure using the AtriCure Isolator Synergy EnCompass-S Ablation System.
Query!
Eligibility
Key inclusion criteria
• 18 years of age or older
• Scheduled for ablation of AF during Coronary Artery Bypass Graft (CABG)or Aortic Valve Replacement (AVR) surgery or a combination
• Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the duration of the study
• Willing and able to give informed consent
• Refractory or intolerant to at least one Class I/III antiarrhythmic agent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
• Contraindication to AF ablation, TEE, or anticoagulation
• Duration of continuous AF lasting longer than 12 months
• History of previous Left Atrium (LA) ablation or surgical treatment of AF/AT/AFL
• AF secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause
• Need for emergent cardiac surgery
• Structural heart disease described as:
• LVEF <30% based on TTE within 6 months of procedure
• Left atrial size > 65mm based on TTE within 6 months of procedure (parasternal view)
• Class IV New York Heart Association (NYHA) heart failure symptoms
• Previous cardiac surgery
• Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
• PCI procedure within the last 3 months
• Documented history of pulmonary hypertension (Class III or IV with a mean pulmonary artery pressure >40 mm Hg)
• Carotid artery stenosis greater than 80%
• Unstable angina or ongoing myocardial ischemia
• Myocardial infarction within the previous 3 months
• History of blood clotting or bleeding disease
• Renal failure requiring dialysis or hepatic failure
• Prior history within the previous 6 months of documented cerebral infarction, TIA or system embolism
• Pregnant or lactating
• Nickel allergy
• Evidence of active infection or endocarditis
• Patient has presence of thrombus in the left atrium or the left atrial appendage, determined by echocardiography (either at baseline TTE (or equivalent diagnostic test) or intraoperative TEE).
• Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcomes measurement for this study
• Any other condition, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
No formal statistical analysis will be performed on these data given the limited sample size. Rather, the primary endpoint is a quantification of the occurrence of the primary safety events through 30 days related to the investigational study device.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
28/02/2025
Query!
Actual
17/03/2025
Query!
Date of last participant enrolment
Anticipated
30/09/2025
Query!
Actual
29/09/2025
Query!
Date of last data collection
Anticipated
31/10/2026
Query!
Actual
30/09/2026
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
10
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
27199
0
Victorian Heart Hospital - Clayton
Query!
Recruitment postcode(s) [1]
43281
0
3168 - Clayton
Query!
Funding & Sponsors
Funding source category [1]
317416
0
Commercial sector/Industry
Query!
Name [1]
317416
0
AtriCure, Inc
Query!
Address [1]
317416
0
Query!
Country [1]
317416
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
ClinTrail Pty
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319699
0
Commercial sector/Industry
Query!
Name [1]
319699
0
AtriCure, Inc
Query!
Address [1]
319699
0
Query!
Country [1]
319699
0
United States of America
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
316287
0
Monash Health Human Research Ethics Committee A
Query!
Ethics committee address [1]
316287
0
https://monashhealth.org/research/resources/resource-library/
Query!
Ethics committee country [1]
316287
0
Australia
Query!
Date submitted for ethics approval [1]
316287
0
06/11/2024
Query!
Approval date [1]
316287
0
19/02/2025
Query!
Ethics approval number [1]
316287
0
Query!
Summary
Brief summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide. Surgical ablation for the treatment of AF during concomitant cardiac surgery is a class I recommendation per STS and HRS guidelines. The AtriCure Isolator Synergy EnCompass-S Ablation System will be used to treat AF as part of planned cardiac surgery. The objective of Encompass-S First in Human study is to evaluate the performance of Encompass-S in patients undergoing AF ablation concomitant to cardiac surgery.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
136902
0
Prof Jayme Bennetts
Query!
Address
136902
0
Victorian Heart Hospital, 631 Blackburn Rd, Clayton VIC 3168
Query!
Country
136902
0
Australia
Query!
Phone
136902
0
+61 410 653 200
Query!
Fax
136902
0
Query!
Email
136902
0
[email protected]
Query!
Contact person for public queries
Name
136903
0
Jess Lampert
Query!
Address
136903
0
AtriCure, Inc. 7555 Innovation Way Mason, Ohio 45040
Query!
Country
136903
0
United States of America
Query!
Phone
136903
0
+1 513 755 4100
Query!
Fax
136903
0
Query!
Email
136903
0
[email protected]
Query!
Contact person for scientific queries
Name
136904
0
Jess Lampert
Query!
Address
136904
0
AtriCure, Inc. 7555 Innovation Way Mason, Ohio 45040
Query!
Country
136904
0
United States of America
Query!
Phone
136904
0
+1 513 755 4100
Query!
Fax
136904
0
Query!
Email
136904
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF